Investor Presentaiton

ILT3 is highly prevalent in myeloid cells in the tumor microenvironment of different cancer types IHC staining of ILT3 (red staining) and CD68 (blue staining) ILT3 levels in various cancers (IHC) Breast cancer Kidney cancer H&N cancer Lung cancer 100 90 Sarcoma Stomach cancer Ovarian cancer % cases positive for ILT3 2000 70 60 50 40 30 20 10 80 Breast cancer Kidney H&N Lung Sarcoma Gastric Ovarian cancer cancer cancer cancer cancer BIOND BIOLOGICS Arrows point to double- positive cells Cases were considered Target -positive if >200 ILT3+ cells were detected Biond Biologics Corporate Presentation | May 2021 | Non-confidential 28

View entire presentation